Objective: To investigate the efficacy and side effect of topical beta-blocker (Timolol Maleate) in the treatment of periocular hemangioma in a prospective study.
Methods: 432 outpatients with infantile hemangioma visited our special clinic service in Shanghai Ninth People's Hospital from July 2010 to December 2011. Among them, 12 superficial periocular lesions were selected in the study. Timolol was used topically on the lesion in every 12 hours. Two independent special doctors evaluated the results according to the pictures before and after four-week application of timolol.
Results: Were categorized into four levels: continuous growth (the lesion continues to grow), stable (no visible change), moderate (0-50% of regression) , perfect (more than 50% of improvement). Result of the 12 outpatients, 4 showed perfect result, 2 moderate, 4 stable and 2 continuous growth. No side effect was observed.
Conclusions: Topical timolol is effective and safe in the treatment of superficial periocular infantile hemangioma. It could be considered as the first line treatment of proliferative superficial hemangioma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Sustained Release of RNA Nanoparticles from Reservoir Implant for Ocular Delivery.
J Pharm Sci
December 2024
Division of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267. Electronic address:
Article Synopsis
- RNA nanoparticles show promise for ocular delivery, particularly for chronic eye diseases, using a periocular reservoir implant like an episcleral implant.
- The study aimed to create these implants, test their release performance with model substances and RNA nanoparticles, and apply hindered transport theory to analyze the release rates.
- Findings showed that the release rates depended on both the size of the substances and the implant membrane's characteristics, indicating a potential for extended delivery of RNA nanoparticles through this implantation method.
Umbilical Amniotic Tissue Graft as an Alternative Approach for Eyelid Reconstruction After Necrotizing Fasciitis Debridement.
Ophthalmic Plast Reconstr Surg
January 2025
Department of Ophthalmology and Visual Sciences, University of Michigan W.K. Kellogg Eye Center, Ann Arbor, Michigan, U.S.A.
A 54-year-old female with myelodysplastic syndrome on chemotherapy presented with 10 days of periocular erythema and edema worsening on oral antibiotics. Computed Tomography scan showed periorbital soft tissue swelling without postseptal extension or abscess. Intravenous broad-spectrum antibiotics were administered.
View Article and Find Full Text PDFThe Surgical Management of the Eye in Facial Palsy.
Facial Plast Surg
December 2024
Department of ENT and Facial Plastic Surgery, The Royal National ENT & Eastman Dental Hospital, University College London NHS Foundation Trust, London, United Kingdom.
The surgical management of the periocular region in facial palsy is a critical aspect of addressing the ocular morbidity associated with facial paralysis. The reconstruction around the eye in facial palsy should take into account the duration of the facial palsy and underlying ocular pathologies. Exposure keratopathy can develop secondary to lagophthalmos, ectropion, and brow ptosis.
View Article and Find Full Text PDFCombined Application of Hyaluronidase and Collagenase for Late-Onset Edema in Periocular Area After Hyaluronic Acid Volume Repositioning: A Six-Case Retrospective Review.
Cureus
November 2024
Oculoplastic Surgery, Sociedad Internacional de Rejuvenecimiento Facial No Quirúrgico (SIRF), Barranquilla, COL.
Background And Objective: Although generally low-risk, hyaluronic acid (HA) dermal fillers can lead to late-onset edema, particularly in the periocular region. This condition typically manifests three to four months post-injection and requires specialized management, usually with hyaluronidase. However, increased use of hyaluronidase has resulted in instances of post-hyaluronidase syndrome, leading to unaesthetic outcomes.
View Article and Find Full Text PDFSelective midfacial neurectomy for postparalytic facial nerve syndrome.
J Plast Reconstr Aesthet Surg
November 2024
Department of Plastic and Reconstructive Surgery, Ichikawa General Hospital, Tokyo Dental College, Ichikawa, Japan.
Chemodenervation with botulinum A toxin and neuromuscular retraining therapy are commonly performed as first-line treatments for postparalytic facial nerve syndrome (PFS). However, their effects are temporary, and side effects typically develop. Currently available selective neurectomy approaches are limited by variations in the anatomy of the peripheral branches of the facial nerve and the ability to reduce perioral synkinesis, but not periocular synkinesis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!